Skip to main content

Immunocore Holdings plc

IMCR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001671927

No open-market purchases or sales by Immunocore Holdings plc insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $1.65B in total; no superinvestor holds it.

Q1 2025 vs. Q4 2024

How the institutions holding Immunocore Holdings plc changed between Q4 2024 and Q1 2025.

All holders in Q1 2025All holders in Q4 2024

13F holders of IMCR: Q4 2024 compared with Q1 2025
MeasureQ4 2024Q1 2025Change
Holders116117+1
Shares45.4M47.3M+1.88M (+4.1%)
Value$1.34B$1.40B+$63.5M (+4.7%)

New holders (15)

Institutions that held Immunocore Holdings plc at the end of Q1 2025 but not at the end of Q4 2024.

Institutions new to IMCR in Q1 2025
InstitutionSharesValue% of portfolio
Cantor Fitzgerald, L. P.100,000$2.97M0.11%
Diadema Partners LP96,984$2.88M2.30%
Tudor Investment Corp Et Al54,493$1.62M0.01%
Caption Management, LLC29,393$872.1K0.04%
Persistent Asset Partners Ltd22,330$662.5K0.58%
Virtus Investment Advisers, Inc.11,847$351.5K0.10%
SEI Investments Co10,736$318.5K0.00%
Checkpoint Capital L.P.9,011$267.4K0.15%
Oppenheimer Asset Management Inc.7,574$224.7K0.00%
UBS Asset Management Americas Inc2,900$86.0K0.00%
Coldstream Capital Management Inc876$26.0K0.00%
Lowe Wealth Advisors, LLC330$9.79K0.00%
EverSource Wealth Advisors, LLC96$2.85K0.00%
Caitong International Asset Management Co., Ltd27$8010.00%
Park Place Capital Corp26$7710.00%

Sold out (14)

Institutions that held Immunocore Holdings plc at the end of Q4 2024 and filed for Q1 2025 without it.